Morgan Stanley
QTTB icon

Morgan Stanley’s Q32 Bio QTTB Stock Holding History

Morgan Stanley’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.4K Buy
9,560
+4,082
+75% +$19.4K ﹤0.01% 6342
2025
Q4 		$18.2K Sell
5,478
-5,865
-52% -$16.6K ﹤0.01% 6720
2025
Q3 		$22.5K Sell
11,343
-7,305
-39% -$14K ﹤0.01% 6657
2025
Q2 		$27.8K Buy
18,648
+3,991
+27% +$6.8K ﹤0.01% 6536
2025
Q1 		$24.2K Sell
14,657
-58,205
-80% -$157K ﹤0.01% 6506
2024
Q4 		$251K Buy
72,862
+56,346
+341% +$1.78M ﹤0.01% 5705
2024
Q3 		$737K Buy
16,516
+9,758
+144% +$359K ﹤0.01% 5219
2024
Q2 		$121K Buy
6,758
+6,035
+835% +$144K ﹤0.01% 5895
2024
Q1 		$12.3K Sell
723
-728
-50% -$10K ﹤0.01% 6629
2023
Q4 		$15.9K Buy
1,451
+730
+101% +$10.7K ﹤0.01% 6726
2023
Q3 		$15.2K Hold
721
– – ﹤0.01% 6570
2023
Q2 		$11.5K Sell
721
-8,088
-92% -$145K ﹤0.01% 6769
2023
Q1 		$163K Buy
8,809
+7,778
+754% +$194K ﹤0.01% 5797
2022
Q4 		$23.4K Sell
1,031
-2,189
-68% -$58.1K ﹤0.01% 6622
2022
Q3 		$93K Sell
3,220
-2,698
-46% -$110K ﹤0.01% 6117
2022
Q2 		$210K Buy
5,918
+258
+5% +$8.81K ﹤0.01% 5873
2022
Q1 		$310K Sell
5,660
-9,682
-63% -$601K ﹤0.01% 5674
2021
Q4 		$1M Buy
15,342
+7,132
+87% +$692K ﹤0.01% 5063
2021
Q3 		$1.16M Sell
8,210
-4,283
-34% -$546K ﹤0.01% 4959
2021
Q2 		$1.63M Buy
12,493
+10,719
+604% +$1.34M ﹤0.01% 4788
2021
Q1 		$301K Sell
1,774
-5,269
-75% -$1.11M ﹤0.01% 5424
2020
Q4 		$1.43M Buy
7,043
+3,114
+79% +$602K ﹤0.01% 4426
2020
Q3 		$757K Buy
3,929
+3,256
+484% +$730K ﹤0.01% 4406
2020
Q2 		$185K Buy
673
+424
+170% +$113K ﹤0.01% 5110
2020
Q1 		$70K Sell
249
-1,782
-88% -$546K ﹤0.01% 5336
2019
Q4 		$757K Buy
2,031
+1,509
+289% +$432K ﹤0.01% 4697
2019
Q3 		$171K Buy
522
+83
+19% +$28.2K ﹤0.01% 5216
2019
Q2 		$155K Buy
439
+191
+77% +$75.1K ﹤0.01% 5133
2019
Q1 		$124K Sell
248
-1,241
-83% -$555K ﹤0.01% 5300
2018
Q4 		$599K Buy
1,489
+61
+4% +$23.1K ﹤0.01% 4672
2018
Q3 		$588K Sell
1,428
-464
-25% -$158K ﹤0.01% 4906
2018
Q2 		$695K Buy
+1,892
New +$677K ﹤0.01% 4875

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley's QTTB Position: Q1 2026 in Review

Morgan Stanley increased its Q32 Bio (QTTB) stake by 75% in Q1 2026, buying an estimated $19.4K and bringing the position to 9,560 shares worth $61.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6342.

Morgan Stanley first reported a position in QTTB in Q2 2018 and has held it in 32 quarters since. The position peaked at $1.63M in Q2 2021. 54 funds tracked by Wall St. Rank hold QTTB as of Q1 2026.

  • Morgan Stanley held 9,560 shares of Q32 Bio worth $61.4K as of Q1 2026.
  • Morgan Stanley bought 4,082 Q32 Bio shares in Q1 2026, an estimated $19.4K.
  • Q32 Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6342 holding.
  • Morgan Stanley first reported a position in Q32 Bio in Q2 2018 and has held it in 32 quarters since.
  • Morgan Stanley's Q32 Bio position peaked at $1.63M in Q2 2021.
  • 54 funds tracked by Wall St. Rank held Q32 Bio as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.